Physician profile
Alana Hoffman
NPI 1295231827
$3,984.17
in general payments reported to CMS, 2019-2025
34 companies · $882 in 2025
The $882 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $882 · 2022: $373 · 2023: $1,278 · 2024: $568 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,630 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,630.03 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $470.75 | 2021-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $394.39 | 2021-2025 | |
| Lilly USA, LLC | $309.36 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $290.97 | 2021-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $247.37 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $230.23 | 2021-2025 | |
| Axsome Therapeutics, INC. | $206.68 | 2023-2025 | Auvelity |
| Boston Scientific Corporation | $186.75 | 2021-2023 | Watchman Flx |
| Exact Sciences Corporation | $170.41 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $169.57 | 2021-2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $144.00 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.31 | 2021-2025 | Synjardy, Jardiance |
| Astrazeneca Pharmaceuticals LP | $106.85 | 2021-2024 | Airsupra |
| Insmed, INC. | $101.91 | 2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $100.79 | 2021-2024 | Trelegy Ellipta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $93.07 | 2021-2023 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $88.52 | 2023-2024 | Quviviq |
| Lucid Diagnostics INC. | $59.26 | 2023 | |
| Dexcom, INC. | $57.30 | 2021-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $56.38 | 2022 | |
| Phathom Pharmaceuticals, INC. | $54.77 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.72 | 2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $37.92 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $29.80 | 2021 | |
| Lundbeck LLC | $29.42 | 2023-2024 | Rexulti |
| Organ Recovery Systems, INC. | $25.87 | 2025 | |
| Daiichi Sankyo INC. | $23.81 | 2024 | Injectafer |
| Xeris Pharmaceuticals, INC. | $22.10 | 2022 | |
| Sun Pharmaceutical Industries INC. | $21.86 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.25 | 2025 | Evkeeza |
| Averitas Pharma INC. | $21.14 | 2023 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $15.85 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $15.74 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alana Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.